NRGN and early-onset autosomal dominant Alzheimer disease: Blennow et al., (2019) [18], studied Ng as a neuronal damage marker in symptomatic CJD and Alzheimer’s disease patients (AD), and found that the CSF Ng levels in CJD were increased compared with healthy controls and even with AD, thereby representing a good biomarker to differentiate CJD from AD.